Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Beuselinck

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
Cancer Medicine|April 18, 2017
Characterizing the outcomes of metastatic papillary renal cell carcinomaJohn Connor Wells, Frede Donskov, Anna P Fraccon, et al.
European Urology Oncology|November 3, 2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Jiaming Huang, Elizabeth Pan, et al.
JCI Insight|March 9, 2026
Determinants of pancreatic tropism in metastatic renal cell carcinomaHaitao Xu, Payal Kapur, Alana Christie, et al.
Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
Communications Biology|February 6, 2021
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinomaMaeva Dufies, Annelies Verbiest, Lindsay S Cooley, et al.
Oncoimmunology|July 8, 2022
Trial watch: Dendritic cell (DC)-based immunotherapy for cancerRaquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Oncoimmunology|June 7, 2023
Trial watch: chemotherapy-induced immunogenic cell death in oncologyJenny Sprooten, Raquel S Laureano, Isaure Vanmeerbeek, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
Cancer Medicine|April 18, 2017
Characterizing the outcomes of metastatic papillary renal cell carcinomaJohn Connor Wells, Frede Donskov, Anna P Fraccon, et al.
European Urology Oncology|November 3, 2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Jiaming Huang, Elizabeth Pan, et al.
JCI Insight|March 9, 2026
Determinants of pancreatic tropism in metastatic renal cell carcinomaHaitao Xu, Payal Kapur, Alana Christie, et al.
Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
Communications Biology|February 6, 2021
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinomaMaeva Dufies, Annelies Verbiest, Lindsay S Cooley, et al.
Oncoimmunology|July 8, 2022
Trial watch: Dendritic cell (DC)-based immunotherapy for cancerRaquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Oncoimmunology|June 7, 2023
Trial watch: chemotherapy-induced immunogenic cell death in oncologyJenny Sprooten, Raquel S Laureano, Isaure Vanmeerbeek, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
Pageof 12